Pigment Epithelium Derived Factor Suppresses Expression of Sost/Sclerostin by Osteocytes: Implication for Its Role in Bone Matrix Mineralization

Journal of Cellular Physiology

Volumn 230, Issue 6, 2015, Pages 1243-1249

  Li, Feng ^a   Song, Na ^a,b   Tombran Tink, Joyce ^a   Niyibizi, Christopher ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BONE SIALOPROTEIN; COLLAGEN TYPE 1; DENTIN MATRIX PROTEIN 1; GLYCOGEN SYNTHASE KINASE 3BETA; HOMOLOGIES TO ENDOPEPTIDASES ON THE X CHROMOSOME PROTEIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; OSTEOCALCIN; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN; PROTEINASE; SCLEROSTIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN; CTNNB1 PROTEIN, HUMAN; EYE PROTEIN; GENETIC MARKER; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; SOST PROTEIN, HUMAN;

ARTICLE; BONE MINERALIZATION; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; OSTEOBLAST; OSTEOCYTE; OSTEOGENESIS IMPERFECTA; OSTEOGENESIS IMPERFECTA TYPE VI; PRIORITY JOURNAL; PROTEIN SYNTHESIS; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ADULT; AGED; BONE MATRIX; GENETIC MARKER; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; BETA CATENIN; BONE MATRIX; BONE MORPHOGENETIC PROTEINS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELLS, CULTURED; EYE PROTEINS; GENETIC MARKERS; HUMANS; MIDDLE AGED; NERVE GROWTH FACTORS; OSTEOCYTES; SERPINS;

EID: 84923303724     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24859     Document Type: Article

References (43)

1. Addison WN, Nakano Y, Loisel T, Crine P, McKee MD. 2008. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: An inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23:1638-1649.
2. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM. 2011. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 26:1425-1436.
3. Baron R, Rawadi G. 2007. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635-2643.
4. Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrbach M, Koerber F, Zimmermann K, de Vries P, Wirth B, Schoenau E, Wollnik B, Veltman JA, Hoischen A, Netzer C. 2011. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 88:362-371.
5. Bellido T, Saini V, Pajevic PD. 2013. Effects of PTH on osteocyte function. Bone 54:250-257.
6. Bogan R, Riddle RC, Li Z, Kumar S, Nandal A, Faugere MC, Boskey A, Crawford SE, Clemens TL. 2013. A mouse model for human osteogenesis imperfecta type VI. J Bone Miner Res 28:1531-1536.
7. Bonewald LF, Johnson ML. 2008. Osteocytes, mechanosensing and Wnt signaling. Bone 42:606-615.
8. Bonnet N, Conway SJ, Ferrari SL. 2012. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci USA 109:15048-15053.
9. Boskey AL, Chiang P, Fermanis A, Brown J, Taleb H, David V, Rowe PS. 2010. MEPE's diverse effects on mineralization. Calcif Tissue Int 86:42-46.
10. Burgers TA, Williams BO. 2013. Regulation of Wnt/beta-catenin signaling within and from osteocytes. Bone 54:244-249.
11. Cai J, Jiang WG, Grant MB, Boulton M. 2006. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281:3604-3613.
12. Capulli M, Paone R, Rucci N. 2014. Osteoblast and osteocyte: Games without frontiers. Arch Biochem Biophys 561:3-12.
13. Chung C, Doll JA, Stellmach VM, Gonzales J, Surapureddi S, Cornwell M, Reddy JK, Crawford SE. 2008. Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha. Adv Exp Med Biol 617:591-597.
14. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. 1999. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 285:245-248.
15. DiGirolamo DJ, Clemens TL, Kousteni S. 2012. The skeleton as an endocrine organ. Nature Rev Rheumatol 8:674-683.
16. Gartland A, Rumney RM, Dillon JP, Gallagher JA. 2012. Isolation and culture of human osteoblasts. Methods Mol Biol 806:337-355.
17. Gattu AK, Swenson ES, Iwakiri Y, Samuel VT, Troiano N, Berry R, Church CD, Rodeheffer MS, Carpenter TO, Chung C. 2013. Determination of mesenchymal stem cell fate by pigment epithelium-derived factor (PEDF) results in increased adiposity and reduced bone mineral content. FASEB J 27:4384-4394.
18. Gericke A, Qin C, Sun Y, Redfern R, Redfern D, Fujimoto Y, Taleb H, Butler WT, Boskey AL. 2010. Different forms of DMP1 play distinct roles in mineralization. J Dent Res 89:355-359.
19. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. 2002. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:30-38.
20. Gordon JAR, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA. 2007. Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 41:462-473.
21. Gu G, Nars M, Hentunen TA, Metsikko K, Vaananen HK. 2006. Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res 323:263-271.
22. Gvritishvili AG, Leung KW, Tombran-Tink J. 2010. Codon preference optimization increases heterologous PEDF expression. PLoS One 5:e15056.
23. Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, White L, Miki R, Cohn DH, Crawford S, Travers R, Glorieux FH, Lee B. 2011. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res 26:2798-2803.
24. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Lowik CW, ten Dijke. 2010. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285:41614-41626.
25. Li F, Song N, Tombran-Tink J, Niyibizi C. 2013. Pigment epithelium-derived factor enhances differentiation and mineral deposition of human mesenchymal stem cells. Stem Cells 31:2714-2723.
26. Li F, Wang X, Niyibizi C. 2007. Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation. Stem Cells 25:3183-3193.
27. Marini JC, Reich A, Smith SM. 2014. Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation. Curr Opin Pediatr 26:500-507.
28. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS. 2008. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757-1772.
29. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. 2010. Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int 87:99-107.
30. Murshed M, Schinke T, McKee MD, Karsenty G. 2004. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165:625-630.
31. Neve A, Corrado A, Cantatore FP. 2013. Osteocalcin: Skeletal and extra-skeletal effects. J Cell Physiol 228:1149-1153.
32. Pagani F, Francucci CM, Moro L. 2005. Markers of bone turnover: biochemical and clinical perspectives. J Endocrino Invest 28(10 Suppl) 8-13.
33. Park K, Lee K, Zhang B, Zhou T, He X, Gao G, Murray AR, Ma JX. 2011. Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol 31:3038-3051.
34. Quan GM, Ojaimi J, Li Y, Kartsogiannis V, Zhou H, Choong PF. 2005. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif Tissue Int 76:146-153.
35. Rossini M, Gatti D, Adami S. 2013. Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121-132.
36. Sekiya H, Mikuni-Takagaki Y, Kondoh T, Seto K. 1999. Synergistic effect of PTH on the mechanical responses of human alveolar osteocytes. Biochem Bioph Res Co 264:719-723.
37. Song N, Armstrong AD, Li F, Ouyang H, Niyibizi C. 2014. Multipotent mesenchymal stem cells from human subacromial bursa: Potential for cell based tendon tissue engineering. Tissue Eng Part A 20:239-249.
38. Staines KA, MacRae VE, Farquharson C. 2012. The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 214:241-255.
39. Steiglitz BM, Ayala M, Narayanan K, George A, Greenspan DS. 2004. Bone morphogenetic protein-1/Tolloid-like proteinases process dentin matrix protein-1. J Biol Chem 279:980-986.
40. Stern AR, Stern MM, Van Dyke ME, Jahn K, Prideaux M, Bonewald LF. 2012. Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice. Biotechniques 52:361-373.
41. Tombran-Tink J, Barnstable CJ. 2004. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: Possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun 316:573-579.
42. Tombran-Tink J, Chader GG, Johnson LV. 1991. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 53:411-414.
43. Venturi G, Gandini A, Monti E, Dalle Carbonare, Corradi L, Vincenzi M, Valenti M, Valli MT, Pelilli M, Boner E, Mottes A, Antoniazzi M. 2012. Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor, causes progressively deforming osteogenesis imperfecta with normal type I collagen. J Bone Miner Res 27:723-728.